Enanta Pharmaceuticals
ENTA
98 hedge funds and large institutions have $419M invested in Enanta Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 23 reducing their positions, and 9 closing their positions.
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
100% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 23
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more capital invested
Capital invested by funds: $339M → $419M (+$80M)
21% more funds holding
Funds holding: 81 → 98 (+17)
15% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $1.17M
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$441K | -10,000 | Closed |
|
102
Massachusetts Financial Services
Boston,
Massachusetts
| – | -$267K | -6,670 | Closed |
|
|
GPGA
103
Grandeur Peak Global Advisors
Salt Lake City,
Utah
| – | -$64K | -1,600 | Closed |
|
104
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
| – | -$52K | -1,300 | Closed |
|
|
JC
105
JBF Capital
Aspen,
Colorado
| – | -$46K | -1,139 | Closed |
|
106
Creative Planning
Overland Park,
Kansas
| – | -$28K | -706 | Closed |
|
|
GC
107
Globeflex Capital
San Diego,
California
| – | -$2K | -55 | Closed |
|
ENTA Hedge Fund Activity: Q2 2014 in Review
98 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2014, worth a combined $419M — up 24% from $339M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ENTA positions and 9 closed out — a net gain of 17 holders — while 46 added to existing stakes and 23 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $17.7M.
- 98 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2014, up from 81 in Q1 2014.
- Funds reported $419M of Enanta Pharmaceuticals stock for Q2 2014, up 24% quarter-over-quarter.
- 26 funds opened new Enanta Pharmaceuticals positions in Q2 2014 and 9 closed out, a net change of +17 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2014 was Consonance Capital Management, an estimated $11.1M added.
- The largest Enanta Pharmaceuticals seller in Q2 2014 was Fidelity Investments, an estimated $17.7M sold.
Based on aggregated 13F filings for Q2 2014.